Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 117

1.

A TIR domain variant of MyD88 adapter-like (Mal)/TIRAP results in loss of MyD88 binding and reduced TLR2/TLR4 signaling.

Nagpal K, Plantinga TS, Wong J, Monks BG, Gay NJ, Netea MG, Fitzgerald KA, Golenbock DT.

J Biol Chem. 2009 Sep 18;284(38):25742-8. doi: 10.1074/jbc.M109.014886.

2.

MyD88 adapter-like (Mal)/TIRAP interaction with TRAF6 is critical for TLR2- and TLR4-mediated NF-kappaB proinflammatory responses.

Verstak B, Nagpal K, Bottomley SP, Golenbock DT, Hertzog PJ, Mansell A.

J Biol Chem. 2009 Sep 4;284(36):24192-203. doi: 10.1074/jbc.M109.023044.

3.

Identification of binding sites for myeloid differentiation primary response gene 88 (MyD88) and Toll-like receptor 4 in MyD88 adapter-like (Mal).

Bovijn C, Desmet AS, Uyttendaele I, Van Acker T, Tavernier J, Peelman F.

J Biol Chem. 2013 Apr 26;288(17):12054-66. doi: 10.1074/jbc.M112.415810.

4.

Molecular analysis of the binding mode of Toll/interleukin-1 receptor (TIR) domain proteins during TLR2 signaling.

Nada M, Ohnishi H, Tochio H, Kato Z, Kimura T, Kubota K, Yamamoto T, Kamatari YO, Tsutsumi N, Shirakawa M, Kondo N.

Mol Immunol. 2012 Oct;52(3-4):108-16. doi: 10.1016/j.molimm.2012.05.003.

PMID:
22673208
5.

Distinct pathways of LPS-induced NF-kappa B activation and cytokine production in human myeloid and nonmyeloid cells defined by selective utilization of MyD88 and Mal/TIRAP.

Andreakos E, Sacre SM, Smith C, Lundberg A, Kiriakidis S, Stonehouse T, Monaco C, Feldmann M, Foxwell BM.

Blood. 2004 Mar 15;103(6):2229-37.

6.

Structural basis for the multiple interactions of the MyD88 TIR domain in TLR4 signaling.

Ohnishi H, Tochio H, Kato Z, Orii KE, Li A, Kimura T, Hiroaki H, Kondo N, Shirakawa M.

Proc Natl Acad Sci U S A. 2009 Jun 23;106(25):10260-5. doi: 10.1073/pnas.0812956106.

7.

TRAM is involved in IL-18 signaling and functions as a sorting adaptor for MyD88.

Ohnishi H, Tochio H, Kato Z, Kawamoto N, Kimura T, Kubota K, Yamamoto T, Funasaka T, Nakano H, Wong RW, Shirakawa M, Kondo N.

PLoS One. 2012;7(6):e38423. doi: 10.1371/journal.pone.0038423.

8.

MyD88 adapter-like (Mal) is phosphorylated by Bruton's tyrosine kinase during TLR2 and TLR4 signal transduction.

Gray P, Dunne A, Brikos C, Jefferies CA, Doyle SL, O'Neill LA.

J Biol Chem. 2006 Apr 14;281(15):10489-95. Erratum in: J Biol Chem. 2016 Dec 9;291(50):26240.

9.

Targeting Toll-like receptor (TLR) signaling by Toll/interleukin-1 receptor (TIR) domain-containing adapter protein/MyD88 adapter-like (TIRAP/Mal)-derived decoy peptides.

Couture LA, Piao W, Ru LW, Vogel SN, Toshchakov VY.

J Biol Chem. 2012 Jul 13;287(29):24641-8. doi: 10.1074/jbc.M112.360925.

10.

Mal (MyD88-adapter-like) is required for Toll-like receptor-4 signal transduction.

Fitzgerald KA, Palsson-McDermott EM, Bowie AG, Jefferies CA, Mansell AS, Brady G, Brint E, Dunne A, Gray P, Harte MT, McMurray D, Smith DE, Sims JE, Bird TA, O'Neill LA.

Nature. 2001 Sep 6;413(6851):78-83.

PMID:
11544529
11.

NF-kappaB activation by the Toll-IL-1 receptor domain protein MyD88 adapter-like is regulated by caspase-1.

Miggin SM, PĂ„lsson-McDermott E, Dunne A, Jefferies C, Pinteaux E, Banahan K, Murphy C, Moynagh P, Yamamoto M, Akira S, Rothwell N, Golenbock D, Fitzgerald KA, O'Neill LA.

Proc Natl Acad Sci U S A. 2007 Feb 27;104(9):3372-7. Erratum in: Proc Natl Acad Sci U S A. 2013 Oct 22;110(43):17600.

12.

Crystal structure of Toll-like receptor adaptor MAL/TIRAP reveals the molecular basis for signal transduction and disease protection.

Valkov E, Stamp A, Dimaio F, Baker D, Verstak B, Roversi P, Kellie S, Sweet MJ, Mansell A, Gay NJ, Martin JL, Kobe B.

Proc Natl Acad Sci U S A. 2011 Sep 6;108(36):14879-84. doi: 10.1073/pnas.1104780108.

14.

In silico approach to inhibition of signaling pathways of Toll-like receptors 2 and 4 by ST2L.

Basith S, Manavalan B, Govindaraj RG, Choi S.

PLoS One. 2011;6(8):e23989. doi: 10.1371/journal.pone.0023989.

15.

MyD88 adaptor-like D96N is a naturally occurring loss-of-function variant of TIRAP.

George J, Kubarenko AV, Rautanen A, Mills TC, Colak E, Kempf T, Hill AV, Nieters A, Weber AN.

J Immunol. 2010 Mar 15;184(6):3025-32. doi: 10.4049/jimmunol.0901156.

16.

TRAM is required for TLR2 endosomal signaling to type I IFN induction.

Stack J, Doyle SL, Connolly DJ, Reinert LS, O'Keeffe KM, McLoughlin RM, Paludan SR, Bowie AG.

J Immunol. 2014 Dec 15;193(12):6090-102. doi: 10.4049/jimmunol.1401605.

17.

Mutational analysis identifies residues crucial for homodimerization of myeloid differentiation factor 88 (MyD88) and for its function in immune cells.

Loiarro M, Volpe E, Ruggiero V, Gallo G, Furlan R, Maiorino C, Battistini L, Sette C.

J Biol Chem. 2013 Oct 18;288(42):30210-22. doi: 10.1074/jbc.M113.490946.

18.

Differential role of MyD88 and Mal/TIRAP in TLR2-mediated gastric tumourigenesis.

Kennedy CL, Najdovska M, Tye H, McLeod L, Yu L, Jarnicki A, Bhathal PS, Putoczki T, Ernst M, Jenkins BJ.

Oncogene. 2014 May 8;33(19):2540-6. doi: 10.1038/onc.2013.205.

PMID:
23728346
19.

Caspase-1 targets the TLR adaptor Mal at a crucial TIR-domain interaction site.

Ulrichts P, Bovijn C, Lievens S, Beyaert R, Tavernier J, Peelman F.

J Cell Sci. 2010 Jan 15;123(Pt 2):256-65. doi: 10.1242/jcs.056002.

20.

Non-essential role for TLR2 and its signaling adaptor Mal/TIRAP in preserving normal lung architecture in mice.

Ruwanpura SM, McLeod L, Lilja AR, Brooks G, Dousha LF, Seow HJ, Bozinovski S, Vlahos R, Hertzog PJ, Anderson GP, Jenkins BJ.

PLoS One. 2013 Oct 29;8(10):e78095. doi: 10.1371/journal.pone.0078095.

Supplemental Content

Support Center